Genesys Capital — 2019 Investments

2 investments dated 2019 · listed companies and verified rows first · show all

Fusion Pharmaceuticalsfusionpharma.com in 𝕏Apr 2019 · $105M

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

John Valliant(Founder)in

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCap Lumira Ventures Pivotal Life Sciences Seroba Life Sciences Venture Ontario +6 more

Seroba Lifesciencesseroba-lifesciences.com inApr 2019 · $105M

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.

Biotech

Co-investorsCDP Venture Capital Ireland Strategic Investment Fund Adams Street Partners HealthCap OrbiMed Pivotal Life Sciences +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.